Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
160 hedge funds and large institutions have $2.93B invested in Karuna Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 73 increasing their positions, 40 reducing their positions, and 21 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 40
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
2% more funds holding
Funds holding: 157 → 160 (+3)
3% less capital invested
Capital invested by funds: $3.02B → $2.93B (-$90.3M)
39% less call options, than puts
Call options by funds: $6.26M | Put options by funds: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$33.9M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$25.9M |
| 3 |
BlackRock
New York
|
+$21M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$41.9M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$34.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$26.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$9.95M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.82M |
KRTX Hedge Fund Activity: Q2 2021 in Review
160 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q2 2021, worth a combined $2.93B — down 3% from $3.02B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KRTX positions and 21 closed out — a net gain of 4 holders — while 73 added to existing stakes and 40 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $33.9M. The largest seller was CAAS Capital Management, cutting an estimated $41.9M.
- 160 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q2 2021, up from 157 in Q1 2021.
- Funds reported $2.93B of Karuna Therapeutics, Inc. Common Stock stock for Q2 2021, down 3% quarter-over-quarter.
- 25 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q2 2021 and 21 closed out, a net change of +4 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q2 2021 was Wellington Management Group, an estimated $33.9M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q2 2021 was CAAS Capital Management, an estimated $41.9M sold.
Based on aggregated 13F filings for Q2 2021.